Core Insights - CervoMed Inc. has completed a Phase 1 study of a new stable crystal form of neflamapimod, which shows a pharmacokinetic profile that overlaps with the active drug used in previous trials [1][2] - The company plans to initiate a Phase 3 trial for dementia with Lewy bodies (DLB) using a dosing regimen of 50mg three times daily (TID) to ensure therapeutic plasma drug concentrations are achieved [1][2][3] Group 1: Study Results and Dosing Regimen - The selected dose for the Phase 3 study is 50mg TID of the stable crystal form of neflamapimod, increased from 40mg to ensure adequate plasma concentrations [2][3] - The pharmacokinetic profiles of the new formulation and the previously used drug product batch (DP Batch B) are largely overlapping, indicating consistency in drug behavior [2][3] Group 2: Manufacturing and Formulation Improvements - CervoMed has developed a controlled manufacturing process that produces only the stable crystal form of neflamapimod, addressing previous issues with cross-batch variability and underperformance [3] - The new formulation aims to mitigate the challenges faced with earlier drug product batches that contained multiple solid-state forms, which affected bioavailability [3] Group 3: Clinical Development and Efficacy - Neflamapimod is an investigational drug targeting neuroinflammation and synaptic dysfunction, with potential applications in DLB and other degenerative brain disorders [4][7] - Clinical trials have shown that neflamapimod is generally well tolerated and has demonstrated efficacy in improving cognitive and functional outcomes in patients with DLB [5][6]